Perumal, Jai
Balabanov, Roumen
Su, Ray
Chang, Roger
Balcer, Laura J.
Galetta, Steven L.
Avila, Robin L.
Rutledge, Danette
Fox, Robert J.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
https://doi.org/10.1007/s12325-021-01722-w
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study
https://doi.org/10.1007/s40263-022-00950-0
Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis
https://doi.org/10.1007/s40120-023-00461-0
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study
https://doi.org/10.1007/s40263-022-00982-6
Article History
First Online: 13 February 2023
Declarations
:
: This study was sponsored by Biogen. Biogen provided funding for medical writing support in the development of this manuscript and paid the open access fee.
: Jai Perumal has received fees from Acorda, Biogen, Genzyme, and Teva. Roumen Balabanov has received consulting fees from Biogen, Sanofi, and Teva and grant/research support from Biogen. Ray Su and Roger Chang were employees of Biogen at the time of these analyses and may hold stock and/or stock options in Biogen. Robin L. Avila, and Danette Rutledge are employees of and may hold stock and/or stock options in Biogen. Laura Balcer is editor-in-chief of the <i>Journal of Neuro-Ophthalmology</i>. Steven Galetta has received consulting fees from Biogen and Genentech. Robert J. Fox has received personal consulting fees from AB Science, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Greenwich Biosciences, Immunic, Janssen, Novartis, Sanofi, and TG Therapeutics; has served on advisory committees for AB Science, Biogen, Genzyme, Immunic, Janssen, Novartis, Sanofi, and TG Therapeutics; and has received clinical trial contract and research grant funding from Biogen, Novartis, and Sanofi.
: Approval was granted by the Copernicus Group IRB #1 (reference number IRB00001313) at 17 study sites and, at the rest of the study sites, by an independent ethics committee. The study was performed in accordance with Good Clinical Practice guidelines.
: All patients provided written informed consent prior to enrollment in STRIVE.
: Not applicable.
: The datasets generated and/or analyzed during the current study are not publicly available. The authors fully support sharing whenever possible. Requests for de-identified data should be made to Biogen via established company data-sharing policies and processes detailed on the website .
: Not applicable.
: Study conception: JP, RB, LB, SG, RJF. Data collection: JP, RB, LB, SG, RJF. Statistical analysis: RS, RC. All authors were involved in critically reviewing the manuscript for intellectual content and provided final approval of the submitted version. All authors agree to be accountable for this work.